Littérature scientifique sur le sujet « Mavacamten »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Mavacamten ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Mavacamten"
Sparrow, Alexander J., Hugh Watkins, Matthew J. Daniels, Charles Redwood et Paul Robinson. « Mavacamten rescues increased myofilament calcium sensitivity and dysregulation of Ca2+ flux caused by thin filament hypertrophic cardiomyopathy mutations ». American Journal of Physiology-Heart and Circulatory Physiology 318, no 3 (1 mars 2020) : H715—H722. http://dx.doi.org/10.1152/ajpheart.00023.2020.
Texte intégralRohde, John A., Osha Roopnarine, David D. Thomas et Joseph M. Muretta. « Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin ». Proceedings of the National Academy of Sciences 115, no 32 (17 juillet 2018) : E7486—E7494. http://dx.doi.org/10.1073/pnas.1720342115.
Texte intégralMaron, Martin S., Ethan J. Rowin et Barry J. Maron. « Is surgical myectomy challenged by emergence of novel drug therapy with mavacamten ? » Asian Cardiovascular and Thoracic Annals 30, no 1 (janvier 2022) : 11–18. http://dx.doi.org/10.1177/02184923221074414.
Texte intégralSewanan, Lorenzo R., Shi Shen et Stuart G. Campbell. « Mavacamten preserves length-dependent contractility and improves diastolic function in human engineered heart tissue ». American Journal of Physiology-Heart and Circulatory Physiology 320, no 3 (1 mars 2021) : H1112—H1123. http://dx.doi.org/10.1152/ajpheart.00325.2020.
Texte intégralReyes, Klevin Roger L., Gizem Bilgili et Florian Rader. « Mavacamten : A First-in-class Oral Modulator of Cardiac Myosin for the Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy ». Heart International 16, no 2 (2022) : 91. http://dx.doi.org/10.17925/hi.2022.16.2.91.
Texte intégralQuintana, Eduard, Pietro Bajona et Patrick O. Myers. « Mavacamten for hypertrophic obstructive cardiomyopathy ». Lancet 397, no 10272 (janvier 2021) : 369. http://dx.doi.org/10.1016/s0140-6736(20)32384-9.
Texte intégralHeitner, Stephen B., Daniel Jacoby, Steven J. Lester, Anjali Owens, Andrew Wang, David Zhang, Joseph Lambing, June Lee, Marc Semigran et Amy J. Sehnert. « Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy ». Annals of Internal Medicine 170, no 11 (30 avril 2019) : 741. http://dx.doi.org/10.7326/m18-3016.
Texte intégralPapadakis, Michael, Joyee Basu et Sanjay Sharma. « Mavacamten : treatment aspirations in hypertrophic cardiomyopathy ». Lancet 396, no 10253 (septembre 2020) : 736–37. http://dx.doi.org/10.1016/s0140-6736(20)31793-1.
Texte intégralJacoby, Daniel, Carolyn Y. Ho, Steven J. Lester, Andrew Wang et Iacopo Olivotto. « Mavacamten for hypertrophic obstructive cardiomyopathy – Authors' reply ». Lancet 397, no 10272 (janvier 2021) : 369–70. http://dx.doi.org/10.1016/s0140-6736(20)32391-6.
Texte intégralBeinfeld, Molly, Jason H. Wasfy, Surrey Walton, Jyotirmoy Sarker, Emily Nhan, David M. Rind et Steven D. Pearson. « Mavacamten for hypertrophic cardiomyopathy : effectiveness and value ». Journal of Managed Care & ; Specialty Pharmacy 28, no 3 (mars 2022) : 369–75. http://dx.doi.org/10.18553/jmcp.2022.28.3.369.
Texte intégralThèses sur le sujet "Mavacamten"
Aguiar, Tiago Filipe Sá Lopes Ribeiro. « Mavacamten, uma nova terapia revolucionária na HOCM : uma revisão de literatura ». Master's thesis, 2021. https://hdl.handle.net/10216/134544.
Texte intégralHypertrophic cardiomyopathy (HCM) is one of the most common inherited cardiac diseases, defined as a left ventricular wall thickness of ≥15 mm, in the absence of other causes of abnormal ventricular loading. A major hallmark of this disease is the presence of left ventricular outflow tract obstruction, which develops in up to ¾ of the patients, referred to as obstructive hypertrophic cardiomyopathy. Current treatment is offered to symptomatic patients, based on the presence of documented left ventricular obstruction, aimed at reducing symptoms and disease progression. This is achieved through pharmacological empirical therapy, surgery, alcohol ablation and/or pacing. Mavacamten is a first-in-class allosteric inhibitor of cardiac myosin that promises to provide clinicians with targeted therapy for these patients. The aim of this review is to provide a general overview of the modern approach in diagnosis and management of HCM, as well as to integrate all the current knowledge on Mavacamten, anticipating a future change in the treatment algorithm of patients with HCM.
Aguiar, Tiago Filipe Sá Lopes Ribeiro. « Mavacamten, uma nova terapia revolucionária na HOCM : uma revisão de literatura ». Dissertação, 2021. https://hdl.handle.net/10216/134544.
Texte intégralHypertrophic cardiomyopathy (HCM) is one of the most common inherited cardiac diseases, defined as a left ventricular wall thickness of ≥15 mm, in the absence of other causes of abnormal ventricular loading. A major hallmark of this disease is the presence of left ventricular outflow tract obstruction, which develops in up to ¾ of the patients, referred to as obstructive hypertrophic cardiomyopathy. Current treatment is offered to symptomatic patients, based on the presence of documented left ventricular obstruction, aimed at reducing symptoms and disease progression. This is achieved through pharmacological empirical therapy, surgery, alcohol ablation and/or pacing. Mavacamten is a first-in-class allosteric inhibitor of cardiac myosin that promises to provide clinicians with targeted therapy for these patients. The aim of this review is to provide a general overview of the modern approach in diagnosis and management of HCM, as well as to integrate all the current knowledge on Mavacamten, anticipating a future change in the treatment algorithm of patients with HCM.
Scellini, Beatrice, Nicoletta Piroddi, Marica Dente, Giulia Vitale, Josè Manuel Pioner, Raffaele Coppini, Cecilia Ferrantini, Corrado Poggesi et Chiara Tesi. « EFFECTS OF MAVACAMTEN, A FIRST-IN-CLASS INHIBITOR OF SARCOMERIC MYOSINS, ON THE MECHANICS OF ATRIAL AND VENTRICULAR MAMMALIAN MYOCARDIUM AND FAST SKELETAL MUSCLE ». Doctoral thesis, 2022. http://hdl.handle.net/2158/1275439.
Texte intégralChapitres de livres sur le sujet "Mavacamten"
Affas, Ziad, Ghaid Touza, Rowaid Touza, Saif Affas, Zain Azzo et Ali Shakir. « Mavacamten a Novel DiseaseSpecific Treatment for Hypertrophic Obstructive Cardiomyopathy : A Meta-Analysis and Systematic Review ». Dans Current Innovations in Medicine and Medical Science Vol. 2, 114–28. Book Publisher International (a part of SCIENCEDOMAIN International), 2022. http://dx.doi.org/10.9734/bpi/cimms/v2/3922a.
Texte intégralActes de conférences sur le sujet "Mavacamten"
Rader, Florian, et Rachel Giles. « Symptomatic obstructive hypertrophic cardiomyopathy : long-term mavacamten control ». Dans 71st ACC Scientific Session, sous la direction de Marc Bonaca. Baarn, the Netherlands : Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/a6a40ff2.
Texte intégralDesai, Milind, et Rachel Giles. « Replacing septal reduction therapy with mavacamten for HCM ». Dans 71st ACC Scientific Session, sous la direction de Marc Bonaca. Baarn, the Netherlands : Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/75909ba6.
Texte intégralForouzandehmehr, "Mohamadamin, Michelangelo Paci, Jussi T. Koivumäki et Jari A. Hyttinen". « Mutation-specific Hypertrophic Cardiomyopathy and Mavacamten : a Mechano-energetic In Silico Study ». Dans 2022 Computing in Cardiology Conference. Computing in Cardiology, 2022. http://dx.doi.org/10.22489/cinc.2022.202.
Texte intégralVara, Sarina, Jason Dungu, Henry Oluwasefunmi Savage et Brian Li. « 32 Mavacamten eligibility in patients with hypertrophic cardiomyopathy attending cardiology clinic in essex, uk ». Dans British Cardiovascular Society Annual Conference, ‘100 years of Cardiology’, 6–8 June 2022. BMJ Publishing Group Ltd and British Cardiovascular Society, 2022. http://dx.doi.org/10.1136/heartjnl-2022-bcs.32.
Texte intégralMargara, Francesca, Blanca Rodriguez, Christopher N. Toepfer et Alfonso Bueno-Orovio. « Mavacamten Efficacy in Mutation-specific Hypertrophic Cardiomyopathy : an In Silico Approach to Inform Precision Medicine ». Dans 2021 Computing in Cardiology (CinC). IEEE, 2021. http://dx.doi.org/10.23919/cinc53138.2021.9662736.
Texte intégral